Ovidiu Boruga

Dr. Ovidiu Boruga


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DCDorina Coricovac
Dorina Coricovac
CRISTINA ADRIANA DEHELEANCRISTINA ADRIANA DEHELEAN
CRISTINA ADRIANA DEHELEAN
Elena Alina MoacaElena Alina Moaca
Elena Alina Moaca
Iulia Andreea PinzaruIulia Andreea Pinzaru
Iulia Andreea Pinzaru
TBTiberiu Bratu
Tiberiu Bratu
OBOvidiu Boruga
Ovidiu Boruga
Cutaneous melanoma is a complex disorder characterized by an elevated degree of heterogeneity, features that place it among the most aggressive types of cancer. Although significant progress was recorded in both the understanding of melanoma biology and genetics, and in therapeutic approaches, this malignancy still represents a major problem worldwide due to its high incidence and the lack of a curative treatment for advanced stages. This review offers a survey of the most recent information available regarding the melanoma epidemiology, etiology, and genetic profile. Also discussed was the topic of cutaneous melanoma murine models outlining the role of these models in understanding the molecular pathways involved in melanoma initiation, progression, and metastasis.

1 January 2018 in Clinical Laboratory
Verified
Journal Article
Closed access
MIMihaela Ivan
Mihaela Ivan
Alexandru Florin RogobeteAlexandru Florin Rogobete
Alexandru Florin Rogobete
OBOvidiu Bedreag
Ovidiu Bedreag
MPMarius Papurica
Marius Papurica
SPSonia Popovici
Sonia Popovici
LFLazar Fulger
Lazar Fulger
Background: A high percentage of the critically ill polytrauma patients develop acute kidney injury (AKI) secondary to trauma and are therefore prone to high morbidity and mortality rates. One of the main objectives in these cases is the fast detection of the condition and continuous rigorous monitoring of the patients. Currently the panel of biomarkers available for monitoring and for the prognosis of AKI is limited. Numerous studies have proven the importance of microRNAs in this field. In this actualization paper we wish to summarize the most relevant microRNAs that can be used as biomarkers for patients with AKI. Methods: For this paper, we looked into the studies available in scientific databases such as PubMed and Scopus. For the analysis we used the following key words: "miRNAs biomarker", "acute kidney injury AKI", "genetic expression in AKI", and "epigenetic microRNAs biomarkers in AKI". Results: Numerous studies have shown high specificity for certain microRNA species in the case of patients with AKI. Moreover, they have reported a series of microRNAs that present high specificity and that have a strong expression in fluids that can be sampled through non-invasive methods, such as urine and saliva. Conclusions: The expression of microRNAs can be successfully used in the future as a non-invasive method for the evaluation and monitoring of AKI patients.